Drugs / FZ002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07649096 | Jul 2026 → Aug 2028 expected | Clostridium difficile colitis | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FZ002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07649096 ↗ |
| Modality | Other / unclassified | “A recombinant live biotherapeutic product (rLBP) for oral administration” NCT07649096 ↗ |
| Route | Oral | “Healthy adults administered 4 capsules of FZ002 orally QH12 for 28 days.” NCT07649096 ↗ |